Pasithea Therapeutics Corp. (KTTA)
| Market Cap | 17.44M +233.4% |
| Revenue (ttm) | n/a |
| Net Income | -24.83M |
| EPS | -0.97 |
| Shares Out | 33.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,368,383 |
| Open | 0.5650 |
| Previous Close | 0.5199 |
| Day's Range | 0.4641 - 0.5800 |
| 52-Week Range | 0.2810 - 2.0600 |
| Beta | 0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About KTTA
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary scle... [Read more]
Financial Performance
Financial StatementsNews
Pasithea Therapeutics price target raised to $4 from $3 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Pasithea Therapeutics (KTTA) to $4 from $3 and keeps a Buy rating on the shares. The firm says the PAS-004-103 data support…
Pasithea Therapeutics Quarterly report: Q3 2026
Pasithea Therapeutics has published its Q3 2026 quarterly earnings report on November 13, 2026.
Pasithea Therapeutics presents clinical data from PAS-004-103 study
Pasithea Therapeutics (KTTA) announced clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1-associated plexiform neurofibromas and a subset of patients with cutaneou...
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activi
Pasithea Therapeutics Transcript: KOL event
PAS-004 is being evaluated as a once-daily chronic MEK inhibitor for PN and cNFs, two NF1 indications with substantial unmet need. KOLs emphasized tolerability, durable exposure, meaningful response measures, and long follow-up as key to adoption and evaluation.
Pasithea gets FDA clearance for Phase 2 PAS-004 trial in skin neurofibromas
Pasithea Therapeutics (KTTA) announced that the FDA has cleared its Investigational New Drug application for a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with neurof...
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . — MI...
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyc...
Pasithea Therapeutics announces PAS-004 data at ESMO
Pasithea Therapeutics (KTTA) announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation study of PAS-004 monotherapy in a heavily pre-treated popula...
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once dai...
Pasithea Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
PAS-004 is being tested in NF1, where cutaneous lesions have substantial unmet need and no approved systemic treatment. Initial Phase Ib data are expected next month, with dose selection for expansion targeted around Q1 or Q2 next year.
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poste...
Pasithea Therapeutics Transcript: AGM 2026
The meeting approved the election of two directors, ratified the independent auditors, and authorized a reverse stock split at a flexible ratio. No questions were raised, and all proposals passed by majority vote.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conferen...
Pasithea Therapeutics Quarterly report: Q2 2026
Pasithea Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Pasithea Therapeutics Proxy statement: Proxy filing
Pasithea Therapeutics filed a proxy statement on August 7, 2026, providing details for shareholder voting and corporate governance matters.
Pasithea Therapeutics Proxy statement: Proxy filing
Pasithea Therapeutics filed a proxy statement on July 29, 2026, providing details for shareholder voting and corporate governance matters.
Pasithea Therapeutics Slides: Corporate presentation
Pasithea Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presen...
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyc...
Pasithea Therapeutics announces updated data from PAS-004 trial
Pasithea Therapeutics (KTTA) announced updated interim safety and clinical activity data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tu...
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal tr...
Pasithea Therapeutics announces amendments to PAS-004 clinical study
Pasithea Therapeutics (KTTA) announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 patients with symptomatic inoperable, incompletely res...